Proteomic profiling in plasma cell disorders: a feasibility study.
Mailankody S et al. Leuk Lymphoma. 2016 Dec 2:1-3. [Epub ahead of print].
Tumor-associated macrophage-mediated survival of myeloma cells through STAT3 activation.
De Beule N et al. J Pathol. 2016 Dec 15. doi: 10.1002/path.4860. [Epub ahead of print].
Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure.
Dao K et al. Cancer Chemother Pharmacol. 2016 Dec 17. [Epub ahead of print].
Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment.
Clemens PL et al. Clin Pharmacokinet. 2016 Nov 29. [Epub ahead of print].
Investigating Effects of Proteasome Inhibitor on Multiple Myeloma Cells Using Confocal Raman Microscopy.
Kang JW et al. Sensors (Basel). 2016 Dec 14;16(12). pii: E2133.
Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry.
Baughn LB et al. Leuk Lymphoma. 2016 Dec 16:1-10. [Epub ahead of print].
MicroRNA-1271 inhibits proliferation and promotes apoptosis of multiple myeloma cells through inhibiting smoothened-mediated Hedgehog signaling pathway.
Xu Z et al. Oncol Rep. 2016 Dec 8. doi: 10.3892/or.2016.5304. [Epub ahead of print].
Polyvalent immunoglobulins, platelet lysate and lenalidomide: cocktail for polyfunctional NK cells expansion for multiple myeloma.
Trébéden-Negre H et al. Bone Marrow Transplant. 2016 Dec 12. doi: 10.1038/bmt.2016.311. [Epub ahead of print].
Polyclonal Immunoglobulin G N-Glycosylation in the Pathogenesis of Plasma Cell Disorders.
Mittermayr S et al. J Proteome Res. 2016 Dec 12. [Epub ahead of print].
Systemic therapy with oncolytic myxoma virus cures established residual multiple myeloma in mice.
Bartee E et al. Mol Ther Oncolytics. 2016 Dec 7;3:16032. eCollection 2016.
Potential Application of 5-Aryl-Substituted 2-Amino- benzamide Type of HDAC1/2-Selective Inhibitors to Pharmaceuticals.
Uesato S et al. Curr Pharm Des. 2016 Dec 8. [Epub ahead of print].
Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells.
Zeng D et al. Oncotarget. 2016 Dec 2. doi: 10.18632/oncotarget.13773. [Epub ahead of print].
Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple Myeloma.
Ou Y et al. J Clin Pharmacol. 2016 Dec 7. doi: 10.1002/jcph.850. [Epub ahead of print].
Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma.
Herrero AB et al. Int J Mol Sci. 2016 Nov 30;17(12). pii: E2003.
In Silico Characterization of miRNA and Long Non-Coding RNA Interplay in Multiple Myeloma.
Ronchetti D et al. Genes (Basel). 2016 Nov 29;7(12). pii: E107.
RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response.
Hofman IJ et al. Leukemia. 2016 Dec 2. doi: 10.1038/leu.2016.370. [Epub ahead of print].
MAX is an epigenetic sensor of 5-carboxylcytosine and is altered in multiple myeloma.
Wang D et al. Nucleic Acids Res. 2016 Nov 29. pii: gkw1184. [Epub ahead of print].
The myeloma stem cell concept, revisited: from phenomenology to operational terms.
Johnsen HE et al. Haematologica. 2016 Dec;101(12):1451-1459.
Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
Abruzzese MP et al. J Hematol Oncol. 2016 Dec 1;9(1):134.
Mitochondrial-Targeted Decyl-Triphenylphosphonium Enhances 2-Deoxy-D-Glucose Mediated Oxidative Stress and Clonogenic Killing of Multiple Myeloma Cells.
Schibler J et al. PLoS One. 2016 Nov 30;11(11):e0167323. doi: 10.1371/journal.pone.0167323. eCollection 2016.
Assessment of oxidative/nitrative modifications of plasma proteins, selected ROTEM parameters and kinetics of fibrinogen polymerization in patients with multiple myeloma at diagnosis.
Nowak W et al. Med Oncol. 2017 Jan;34(1):4. Epub 2016 Nov 30.
Preclinical activity of CPI-0610, a novel small molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma.
Siu KT et al. Leukemia. 2016 Nov 28. doi: 10.1038/leu.2016.355. [Epub ahead of print].
The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment.
Fan F et al. Leukemia. 2016 Dec 16. doi: 10.1038/leu.2016.358. [Epub ahead of print].
Induction of iron excess restricts malignant plasma cells expansion and potentiates bortezomib effect in models of multiple myeloma.
Bordini J et al. Leukemia. 2016 Dec 13. doi: 10.1038/leu.2016.346. [Epub ahead of print].
Low-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and γδ T cell-mediated lysis in multiple myeloma.
Niu C et al. Oncotarget. 2016 Dec 16. doi: 10.18632/oncotarget.13979. [Epub ahead of print].